Opioid drugs are prescribed to relieve severe pain and are highly addictive. Some key products include oxycodone, hydrocodone, codeine, morphine etc. .
Over 200,000 square feet of state-of-the-art and well-equipped solid dose pharmaceutical facilities in Bridgeton and St. Louis, Missouri.SAN DIEGO (BUSINESS WIRE) Heritage Global Partners (“HGP”), a worldwide leader in asset advisory and auction services, and a subsidiary of Heritage Global Inc. (NASDAQ: HGBL), to.
/PRNewswire/ According to Coherent Market Insights, the global opioids market is estimated to be valued at US$ 42,429 million in 2021 and is expected to.
Granules India announced that the US Food & Drug Administration (US FDA) has approved its
Abbreviated New Drug Application (ANDA) for Potassium Chloride Extended-Release Capsules USP, 8 mEq
(600 mg) and 10 mEq (750 mg). It is bioequivalent to the reference listed drug product (RLD), Micro-K
Extended-Release Capsules, 8 mEq and 10 mEq, of Nesher Pharmaceuticals (USA) LLC.
The product would
be manufactured at the company s Hyderabad facility and is expected to be launched shortly.
Potassium Chloride is indicated for the treatment of patients with hypokalemia with or without metabolic
alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. It is also
indicated for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia
Granules India gets USFDA nod for its Potassium Chloride ER Capsules USP
February 17, 2021
×
Granules India Limited has announced that the US Food & Drug Administration has approved its Abbreviated New Drug Application (ANDA) for Potassium Chloride Extended-Release Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg).
It is bioequivalent to the reference listed drug product (RLD), Micro-K Extended-Release Capsules, 8 mEq and 10 mEq, of Nesher Pharmaceuticals (USA) LLC. The product would be manufactured at the company’s Hyderabad facility and is expected to be launched shortly.
“We are pleased to announce approval of Potassium Chloride Capsule product within the first review cycle of 10 months from the filing date. This is fourth ANDA approval in our Potassium Chloride product basket,” said Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals, Inc.